Alexander Tzankov

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Intrasinusoidal bone marrow involvement in mantle cell lymphoma: a case series with review of the main differential diagnoses.

Intrasinusoidal bone marrow involvement in mantle cell lymphoma: a case series with review of the main differential diagnoses.

Journal: Virchows Archiv : an international journal of pathology
Published: April 25, 2024

Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome.

Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome.

Journal: Nature communications
Published: March 21, 2024

Genetic and phenotypic attributes of splenic marginal zone lymphoma.

Genetic and phenotypic attributes of splenic marginal zone lymphoma.

Journal: Blood
Published: May 10, 2021

NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.

NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: September 30, 2016

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 21, 2015

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: July 10, 2015

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Journal: Cancer cell
Published: July 10, 2014

Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 04, 2014

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Journal: Blood
Published: August 29, 2013

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.

Journal: Blood
Published: July 23, 2013

Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.

Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.

Journal: Human pathology
Published: May 04, 2013

Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Journal: Blood
Published: March 22, 2013
Showing 1-12 of 23

Last Updated: 09/26/2026